DDS: 使用利福昔明治疗患有肠易激综合征的海湾退伍军人的疗效分析

2019-04-21 不详 MedSci原创

肠易激综合征(IBS)在参加海湾战争(GW)的退伍军人中发生率高达33%。其中的机制可能为肠道微生物菌群(包括小肠细菌过度生长(SIBO))的改变在IBS的发展中起作用。利福昔明是一种不易被机体吸收的抗生素,也许可以通过恢复正常的肠道微生物群来改善IBS症状。这项研究的目的是比较利福昔明与安慰剂对没有便秘的IBS退伍军人的IBS症状和生活质量(QOL)的改善情况。

背景
肠易激综合征(IBS)在参加海湾战争(GW)的退伍军人中发生率高达33%。其中的机制可能为肠道微生物菌群(包括小肠细菌过度生长(SIBO))的改变在IBS的发展中起作用。利福昔明是一种不易被机体吸收的抗生素,也许可以通过恢复正常的肠道微生物群来改善IBS症状。这项研究的目的是比较利福昔明与安慰剂对没有便秘的IBS退伍军人的IBS症状和生活质量(QOL)的改善情况。

方法
本项研究为一项双盲,安慰剂对照研究。研究人员从数据库中筛选了221名具有IBS(罗马III)的GW退伍军人并转诊到肠病学和内科诊所。50名患者被随机分组,即每天两次接受利福昔明550克或安慰剂,持续2周。主要观察结果为:(1)大便次数,(2)大便稠度(布里斯托尔大便量表),(3)紧迫性(1 =是 0 =没有),( 4)腹痛的严重程度(0-4,无至严重),(5)腹胀的严重程度(1-4,无至严重),和(6)总体改善量表(1-7,严重恶化至显着改善) 。这些记录连续7天,然后取平均值。治疗2周后比较症状数据。使用IBS-QOL评估QOL。乳果糖氢呼气试验(LHBT)在基线和治疗2周后进行。

结果
五十名退伍军人中有3人退出,3人失访。研究人员从44名患者(38名男性,6名女性,中位年龄52岁)进行相关分析。利福昔明与在总体症状显着改善,腹痛,腹胀,大便尿急,尿频无明显相关性(所有的P ≥0.25)。在利福昔明和安慰剂治疗的退伍军人之间,LHBT对SIBO的正常化没有差异(7% VS 22%,P=0.54 )。

结论
利福昔明在改善非便秘IBS的GW退伍军人中的IBS症状和QOL方面无效。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647240, encodeId=3b00164e24038, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Dec 27 05:23:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648683, encodeId=bb981648683ba, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sun Jul 28 21:23:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431495, encodeId=a579143149507, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518493, encodeId=14ec1518493fd, content=<a href='/topic/show?id=ac1b323262a' target=_blank style='color:#2F92EE;'>#利福昔明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32326, encryptionId=ac1b323262a, topicName=利福昔明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895411147722, createdName=showtest, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032133, encodeId=08481032133ff, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 21 17:23:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647240, encodeId=3b00164e24038, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Dec 27 05:23:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648683, encodeId=bb981648683ba, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sun Jul 28 21:23:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431495, encodeId=a579143149507, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518493, encodeId=14ec1518493fd, content=<a href='/topic/show?id=ac1b323262a' target=_blank style='color:#2F92EE;'>#利福昔明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32326, encryptionId=ac1b323262a, topicName=利福昔明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895411147722, createdName=showtest, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032133, encodeId=08481032133ff, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 21 17:23:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647240, encodeId=3b00164e24038, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Dec 27 05:23:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648683, encodeId=bb981648683ba, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sun Jul 28 21:23:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431495, encodeId=a579143149507, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518493, encodeId=14ec1518493fd, content=<a href='/topic/show?id=ac1b323262a' target=_blank style='color:#2F92EE;'>#利福昔明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32326, encryptionId=ac1b323262a, topicName=利福昔明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895411147722, createdName=showtest, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032133, encodeId=08481032133ff, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 21 17:23:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647240, encodeId=3b00164e24038, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Dec 27 05:23:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648683, encodeId=bb981648683ba, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sun Jul 28 21:23:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431495, encodeId=a579143149507, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518493, encodeId=14ec1518493fd, content=<a href='/topic/show?id=ac1b323262a' target=_blank style='color:#2F92EE;'>#利福昔明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32326, encryptionId=ac1b323262a, topicName=利福昔明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895411147722, createdName=showtest, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032133, encodeId=08481032133ff, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 21 17:23:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1647240, encodeId=3b00164e24038, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Dec 27 05:23:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648683, encodeId=bb981648683ba, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sun Jul 28 21:23:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431495, encodeId=a579143149507, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518493, encodeId=14ec1518493fd, content=<a href='/topic/show?id=ac1b323262a' target=_blank style='color:#2F92EE;'>#利福昔明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32326, encryptionId=ac1b323262a, topicName=利福昔明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895411147722, createdName=showtest, createdTime=Tue Apr 23 05:23:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032133, encodeId=08481032133ff, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 21 17:23:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
    2019-04-21 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Curr Opin Clin Nutr Metab Care:肠易激综合征和饮食——2018年我们在哪里?

过去五十年来,关于IBS饮食管理的研究数量急剧增加,研究干预的重点,规模和复杂程度各不相同。最初,许多研究调查膳食纤维在IBS管理中的作用,至少包括14项随机对照试验

GUT:粪便微生物移植改变中重度肠易激综合征患者肠道微生物群但疾病症状缓解效果不理想

通过随机双盲安慰剂对照研究证实,粪便微生物移植可改变肠易激综合征患者肠道微生物多样性,但安慰剂组患者肠易激综合征临床症状的改善效果优于治疗组,肠道微生物群的改变对肠易激综合征临床症状的改善效果不充分

Am J Gastroenterol:粪便微生物移植对肠易激综合征患者的影响

研究认为,没有充分的证据证明粪便微生物移植可改善肠易激综合征患者症状

Gastroenterology:肠易激综合征患者肠道微生物变化研究

研究认为,IBS患者的特异性微生物群落存在变化,但仍需要进行研究来确定这些微生物变化是肠易激综合征的结果还是病因

Gastroenterology:9号染色体变异与女性IBS风险

研究发现9q32.1染色体突变与女性肠易激综合征风险显著相关,表明性激素和自主神经功能障碍在肠易激综合征的病理过程中发挥了重要作用

J Gastroen Hepatol:饮食习惯与青春期肠易激综合征之间的关系

汤泡饭、咀嚼不足、牙齿脱落率高、辛辣和油炸食物导致青春期少女肠易激综合征风险增加